Silence Therapeutics to Webcast Presentations at Upcoming September Investor Conferences

Silence Therapeutics plc, Nasdaq: SLN ("Silence" or the "Company"), a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, today announced that management will present a company overview at the Leerink Partners Global Healthcare Conference on Wednesday, March 12th at 1:00 p.m. ET. The live webcast can be accessed via the Investors section of the Silence website at www.silence-therapeutics.com. An archived replay of the webcast will be available following the conference. About Silence Therapeutics Silence Therapeutics is a global clinical-stage biotechnology company committed to transforming people's lives by silencing diseases through precision engineer

The Company's cash guidance is now extended into 2027 Company to host conference call and webcast today at 8 a.m. EST / 1 p.m. GMT Silence Therapeutics plc, Nasdaq: SLN ("Silence" or "the Company"), a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, today reported its financial results for the full year ended December 31, 2024, and provided a business update. "2024 was marked by strong clinical execution and pipeline advancement, highlighting the broad potential of our mRNAi GOLD™ platform to silence disease causing genes," said Craig Tooman, President and CEO of Silence. "In 2025, we are prioritizing investment in programs targeting rare conditi

Silence Therapeutics plc, Nasdaq: SLN ("Silence" or "the Company"), a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, today announced that the Company will release its financial and business results for the fourth quarter and full year ended December 31, 2024, on Thursday, February 27, 2025. Management will host a conference call at 8:00 a.m. ET / 1:00 p.m. GMT that day to discuss the Company's financial results and provide a general business update. The conference call will be webcast live and available on the Investors section of the Silence website at www.silence-therapeutics.com. The webcast will also be archived on the Company's website. Deta

Goldman initiated coverage of Silence Therapeutics with a rating of Sell and set a new price target of $6.00

BMO Capital Markets reiterated coverage of Silence Therapeutics with a rating of Outperform

Jefferies initiated coverage of Silence Therapeutics with a rating of Buy and set a new price target of $40.00

4 - Silence Therapeutics plc (0001479615) (Issuer)

4 - Silence Therapeutics plc (0001479615) (Issuer)

4 - Silence Therapeutics plc (0001479615) (Issuer)

S-8 - Silence Therapeutics plc (0001479615) (Filer)

10-K - Silence Therapeutics plc (0001479615) (Filer)

8-K - Silence Therapeutics plc (0001479615) (Filer)

Silence Therapeutics plc (NASDAQ:SLN) ("Silence" or the "Company"), an experienced and innovative biotechnology company committed to transforming people's lives by silencing diseases through precision engineered medicines, today announced that Alistair Gray, who has served as an independent member of Silence's Board of Directors (the "Board") since 2015, informed the Company that he will retire from the Board, effective May 1, 2024. Iain Ross, Silence's Chairman of the Board, commented, "Alistair has made significant contributions to the Board and the Company over the past nine years. During his time on the Board, the Company has transitioned into a global player focused on the developmen

Dr. Romano will succeed Dr. Giles Campion, CMO and Head of R&D, following his retirement by year-end Silence Therapeutics plc, Nasdaq: SLN ("Silence" or "the Company"), an experienced and innovative biotechnology company committed to transforming people's lives by silencing diseases through precision engineered medicines, today announced the appointment of Steven Romano, MD, as incoming Chief Medical Officer and Head of Research and Development. Dr. Romano will join Silence on April 1, 2023, and work alongside Giles Campion, MD, current CMO and Head of R&D at Silence, to ensure an efficient and smooth transition for Dr. Campion's retirement by year-end. Dr. Romano has served as non-execut

Silence Therapeutics plc, Nasdaq: SLN ("Silence" or "the Company"), an experienced and innovative biotechnology company committed to transforming people's lives by silencing diseases through precision engineered medicines, today announced the appointment of J.P. Gabriel as Chief Technical Operations Officer following the retirement of Jørgen Wittendorff, SVP, Technical Operations. In this role, J.P. is responsible for Manufacturing, Process and Analytical Development and Supply Chain. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230206005194/en/J.P. Gabriel, Chief Technical Operations Officer, Silence Therapeutics plc. (Photo:

The Company's cash guidance is now extended into 2027 Company to host conference call and webcast today at 8 a.m. EST / 1 p.m. GMT Silence Therapeutics plc, Nasdaq: SLN ("Silence" or "the Company"), a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, today reported its financial results for the full year ended December 31, 2024, and provided a business update. "2024 was marked by strong clinical execution and pipeline advancement, highlighting the broad potential of our mRNAi GOLD™ platform to silence disease causing genes," said Craig Tooman, President and CEO of Silence. "In 2025, we are prioritizing investment in programs targeting rare conditi

Silence Therapeutics plc, Nasdaq: SLN ("Silence" or "the Company"), a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, today announced that the Company will release its financial and business results for the fourth quarter and full year ended December 31, 2024, on Thursday, February 27, 2025. Management will host a conference call at 8:00 a.m. ET / 1:00 p.m. GMT that day to discuss the Company's financial results and provide a general business update. The conference call will be webcast live and available on the Investors section of the Silence website at www.silence-therapeutics.com. The webcast will also be archived on the Company's website. Deta

Divesiran eliminated the need for phlebotomy in all well-controlled patients following infrequent dosing and was well tolerated Data support advancing divesiran into Phase 2 Company to host conference call today at 8:30am Eastern Time Silence Therapeutics plc ("Silence" or the "Company"), (NASDAQ:SLN), an experienced and innovative biotechnology company committed to transforming people's lives by silencing diseases through precision engineered medicines, today announced positive results from the ongoing SANRECO Phase 1 repeat dose study of divesiran (SLN124), a siRNA (short interfering RNA) targeting TMPRSS6, in patients with polycythemia vera (PV). "With today's very exciting PV da

SC 13G/A - Silence Therapeutics plc (0001479615) (Subject)

SC 13G/A - Silence Therapeutics plc (0001479615) (Subject)

SC 13G/A - Silence Therapeutics plc (0001479615) (Subject)